Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Global Clinical Trials Review, 2025" clinical trials has been added to ...

The dynamics of the multiple system atrophy treatment market is anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel ...

Dublin, Nov. 18, 2024 (GLOBE NEWSWIRE) -- The "Multiple System Atrophy (MSA): Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This reports provides a data-driven ...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Multiple System Atrophy (MSA) is a progressive, rare neurodegenerative disorder adversely affecting the autonomic nervous system, movement, balance, coordination, and various bodily functions.

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Latest analysis reveals key trends and opportunities in the Multiple System Atrophy (MSA) market, highlighting advancements in treatment options. BURLINGAME, CA, UNITED STATES, October 30, 2024 ...

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...